Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Terminated 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Psychotic Disorders 1Lymphoma, Follicular 1Head and Neck Neoplasms 1Glioblastoma 1Epilepsy 1Bipolar Disorder 1

Interventions

pembrolizumab 25Cisplatin 17Carboplatin 13Radiotherapy 12Cetuximab 9Blood Specimen Collection 9Docetaxel 8Paclitaxel 7Fluorouracil 7Drug Therapy 7toripalimab 6tislelizumab 4nimotuzumab 4atezolizumab 4Surveys and Questionnaires 4Radiation 4Chemoradiotherapy 4fludarabine 3Surgical Procedures, Operative 3Standard of Care 3Radiotherapy, Intensity-Modulated 3Cyclophosphamide 3Biopsy 3130-nm albumin-bound paclitaxel 3cemiplimab 2avelumab 2X-Rays 2Tocopherols 2Tiragolumab 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Head and Neck Neoplasms × Gabapentin × Clear all
NCT05156060 2024-10-21

Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

Vanderbilt-Ingram Cancer Center

Phase 1/2 Recruiting
64 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡